Research breakthroughs on Inflammatory Bowel Disease (IBD) are fervently sought, aiming to raise global healthcare accessibility, relieve the burden of its life-altering symptoms, improve patients' quality of life, and ultimately, find a cure. Built on these pillars is the Crohn’s & Colitis Foundation – a non-profit organization aiming to find the cure for Crohn's disease and ulcerative colitis established in 1967.
The Foundation spearheads multifaceted initiatives, from funding pioneering research studies to providing educational resources and support networks for patients and caregivers. Through collaborative efforts with medical professionals, researchers, and pharmaceutical companies, the Foundation strives to advance understanding of the underlying mechanisms of IBD and develop more effective treatments.
Just recently, the Foundation hosted the 6th IBD Innovate Conference, which served as an instrumental platform for knowledge exchange and collaboration among startups, innovators, researchers, and industry stakeholders. Among the distinguished guests invited was Nir Salomon, the Co-founder and Head of R&D at Evinature – a healthcare startup that leads cutting-edge research in integrative therapies for IBD. Salomon, also the Founder & Director of the Integrative Gastroenterology unit at Sheba Medical Center, is renowned for advocating integrative, evidence-based therapies. His lecture engagements span the globe, disseminating knowledge ranging from cutting-edge research to esteemed medical communities worldwide. Salomon stated: “Evinature has become a bridge connecting patients, the medical world, and innovation. So connecting with advocates and organizations like CCF is a significant step towards further spearheading advancements in IBD therapy.”
Salomon's invitation to present CurQD® and Evinature’s online platform at the 6th IBD Innovate Conference marked a pivotal moment in the quest for innovative IBD therapeutics. CurQD® is a breakthrough, first-in-class nutraceutical for IBD with high remission rates in patients failing pharmaceutical treatment, as shown in a recently published multicenter RCT. CurQD® is available through Evinature’s revolutionary platform, which facilitates direct-to-patient treatments using data-driven, tailored protocols while providing full clinic support to patients around the world.
At the conference, Salomon had the opportunity to meet with Dr. Alan Moss, Chief Scientific Officer at the Crohn’s & Colitis Foundation. A distinguished clinician-scientist, Dr. Moss has long been at the forefront of IBD research, advocating advancement in patient care. He and Salomon discussed the future trajectory of IBD treatment, sharing expertise from clinical practice and scientific inquiry to chart new frontiers in IBD treatments. “Patients with IBD need a variety of treatment options to address their disease,” Dr. Moss shared. “I was interested to see the CurQD® data shared at Innovate 2024, and look forward to further advances in herbal therapeutics for IBD.”
“The CCF innovator’s conference has a huge impact on patient care, uniting the perspectives of patients, doctors, innovators, researchers, and the industry itself to push IBD treatments forward,” Salomon said. With CurQD® and its promising results illuminating the path towards global healthcare accessibility for IBD, Evinature’s collaborative efforts with CCF offer hope for a future where the burden of IBD is alleviated, one breakthrough at a time. “It’s inspiring to see venture capitalists, innovative startups, patient advocates, and leading researchers in one room, working together to break the therapeutic ceiling and help patients,” he concluded.